# Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181

> **NCT02597114** · PHASE1 · COMPLETED · sponsor: **ArmaGen, Inc** · enrollment: 3 (actual)

## Conditions studied

- Mucopolysaccharidosis I

## Interventions

- **DRUG:** AGT-181

## Key facts

- **NCT ID:** NCT02597114
- **Lead sponsor:** ArmaGen, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-03-19
- **Final completion:** 2018-08-02
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597114, "Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02597114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*